Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Germline variants in exonic regions have limited impact on immune checkpoint blockade clinical outcomes in advanced melanoma.

Pigment cell & melanoma research - 1 Sept 2021

Montaudié Henri, Beranger Guillaume Emmanuel, Reinier Frédéric, Nottet Nicolas, Martin Hélène, Picard-Gauci Alexandra, Troin Laura, Ballotti Robert, Passeron Thierry

Abstract excerpt

Immune checkpoint inhibition (ICI) treatments improve outcomes for metastatic melanoma; however, up to 60% of treated patients do not respond to ICI and/or develop immune-related adverse events (irAEs). Currently, robust and reliable biomarker to predict response and/or occurrence of irAEs to ICI are missing. Herein, we wanted to explore whether germline variants (SNPs) could predict the clinical outcomes of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Exome Sequencing
Share to Exons

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Germ-Line Mutation

Share to Immune Checkpoint Inhibitors

Share to Melanoma

Share to Neoplasm Metastasis

Share to Neoplasm Proteins

Share to Polymorphism, Single Nucleotide

Source

Identifiers

PMID: 33449414
DOI: 10.1111/pcmr.12958

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Germline variants in exonic regions have limited impact on immune checkpoint blockade clinical outcomes in advanced melanoma.PMID 33449414Read ↗

Clinical Impact of Immune Checkpoint Inhibitor (ICI) Response, DNA Damage Repair (DDR) Gene Mutations and Immune-Cell Infiltration in Metastatic Melanoma Subtypes.Semantic proximity Read ↗

Germline Variation in PDCD1 Is Associated with Overall Survival in Patients with Metastatic Melanoma Treated with Anti-PD-1 MonotherapySemantic proximity Read ↗

Genomic and Epigenomic Biomarkers of Immune Checkpoint Immunotherapy Response in Melanoma: Current and Future PerspectivesSemantic proximity Read ↗

Biological Factors behind Melanoma Response to Immune Checkpoint Inhibitors.Semantic proximity Read ↗

Systematic evaluation of the predictive gene expression signatures of immune checkpoint inhibitors in metastatic melanomaSemantic proximity Read ↗

Integrated genomic analysis identifies a genetic mutation model predicting response to immune checkpoint inhibitors in melanoma.Semantic proximity Read ↗

Insights and Strategies of Melanoma Immunotherapy: Predictive Biomarkers of Response and Resistance and Strategies to Improve Response RatesSemantic proximity Read ↗

Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma.Semantic proximity Read ↗

Distinct Mutation Patterns Reveal Melanoma Subtypes and Influence Immunotherapy Response in Advanced Melanoma PatientsSemantic proximity Read ↗

Integrating tumor and immune cell transcriptomics to predict immune checkpoint inhibitor primary resistance in metastatic cutaneous melanomaSemantic proximity Read ↗

Genomic landscape of the immunogenicity regulation in skin melanomas with diverse tumor mutation burden.Semantic proximity Read ↗

Genetic determinants of immune-related adverse events in patients with melanoma receiving immune checkpoint inhibitors.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.